{"id":"ciprofloxacin-single-dose","safety":{"commonSideEffects":[{"rate":"3-17%","effect":"Nausea"},{"rate":"2-16%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Vomiting"},{"rate":"1-7%","effect":"Abdominal pain"},{"rate":"1-2%","effect":"Headache"},{"rate":"1-3%","effect":"Dizziness"},{"rate":"<1%","effect":"Tendinopathy"},{"rate":"<1%","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, ciprofloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA supercoiling and separation. This dual inhibition leads to disruption of DNA replication, transcription, and ultimately bacterial cell death. The single-dose formulation is designed for rapid therapeutic effect in acute infections.","oneSentence":"Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:58.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial infections (respiratory, urinary tract, gastrointestinal, skin)"},{"name":"Gonorrhea (single-dose regimen)"},{"name":"Traveler's diarrhea"}]},"trialDetails":[{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT06810583","phase":"PHASE1","title":"A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-22","conditions":"Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children","enrollment":29},{"nctId":"NCT07202052","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Non-Hodgkin's Lymphoma, Leukemia","enrollment":900},{"nctId":"NCT06798402","phase":"PHASE2","title":"Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate","status":"RECRUITING","sponsor":"Al-Mustafa University College","startDate":"2025-02-07","conditions":"Cutaneous Leishmaniasis","enrollment":80},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT03692715","phase":"PHASE4","title":"Antibiotic Prophylaxis Before Shock Wave Lithotripsy","status":"COMPLETED","sponsor":"Clinical Urology and Epidemiology Working Group","startDate":"2018-09-27","conditions":"Ureteral Stones, Ureteral Calculi, Nephrolithiasis","enrollment":1732},{"nctId":"NCT02944825","phase":"NA","title":"Antibiotic Prophylaxis With Routine Ureteral Stent Removal","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":"Urolithiasis, UTI","enrollment":80},{"nctId":"NCT05843708","phase":"PHASE1","title":"A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects","status":"COMPLETED","sponsor":"Servier Bio-Innovation LLC","startDate":"2023-04-14","conditions":"Healthy Subjects","enrollment":64},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT00649662","phase":"PHASE1","title":"Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT00649155","phase":"PHASE1","title":"Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT00650351","phase":"PHASE1","title":"Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-10","conditions":"Healthy","enrollment":35},{"nctId":"NCT06185543","phase":"PHASE2","title":"A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.","status":"UNKNOWN","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2023-11-19","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT02579161","phase":"PHASE3","title":"Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2014-09","conditions":"Kidney Stones","enrollment":98},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT05205993","phase":"PHASE2","title":"Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis","status":"UNKNOWN","sponsor":"Genesis Athens Clinic","startDate":"2021-01-19","conditions":"Chronic Endometritis","enrollment":90},{"nctId":"NCT05436678","phase":"PHASE1","title":"A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2022-07-26","conditions":"Pharmacokinetics","enrollment":19},{"nctId":"NCT05232461","phase":"PHASE1","title":"A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2022-04-08","conditions":"Pharmacokinetics","enrollment":12},{"nctId":"NCT05532267","phase":"PHASE1","title":"Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-11-04","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT04238091","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata","status":"WITHDRAWN","sponsor":"Lindsey Bordone","startDate":"2019-12-19","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":""},{"nctId":"NCT00142272","phase":"PHASE3","title":"Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2001-05","conditions":"Cholera","enrollment":180},{"nctId":"NCT04870138","phase":"PHASE1","title":"Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-10","conditions":"Gonococcal Infection","enrollment":16},{"nctId":"NCT02033408","phase":"NA","title":"Manipulating the Microbiome in IBD by Antibiotics and FMT","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2014-01","conditions":"Exacerbation of Ulcerative Colitis, Ulcerative Colitis, Active Severe, Crohn's Colitis","enrollment":28},{"nctId":"NCT03177720","phase":"PHASE1","title":"Evaluation of Innovative Tools in Development of Antibiotics","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-05-29","conditions":"Pneumonia","enrollment":10},{"nctId":"NCT00654108","phase":"PHASE1","title":"Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-06-02","conditions":"Gastroenteritis Escherichia Coli","enrollment":62},{"nctId":"NCT01402947","phase":"PHASE1","title":"Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-25","conditions":"Healthy","enrollment":30},{"nctId":"NCT03840811","phase":"PHASE1","title":"Experimental Human Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-04-23","conditions":"Gonococcal Infection","enrollment":27},{"nctId":"NCT04030741","phase":"PHASE2, PHASE3","title":"Non-operative Treatment of Acute Non-perforated Appendicitis","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2018-09-01","conditions":"Acute Appendicitis","enrollment":180},{"nctId":"NCT04621253","phase":"PHASE1","title":"Inhibition Metamizole 2020","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-29","conditions":"Drug-drug Interaction","enrollment":12},{"nctId":"NCT00992329","phase":"PHASE1","title":"Impact of Formulation on Ciprofloxacin Oral Absorption","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT02719158","phase":"PHASE2","title":"Dose Ranging Study of OTO-201 in AOMT","status":"COMPLETED","sponsor":"Otonomy, Inc.","startDate":"2016-02","conditions":"Acute Otitis Media, AOMT","enrollment":95},{"nctId":"NCT02961751","phase":"NA","title":"Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-19","conditions":"Gonococcal Infection","enrollment":211},{"nctId":"NCT03630250","phase":"EARLY_PHASE1","title":"Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA)","status":"COMPLETED","sponsor":"University of Southampton","startDate":"2018-10-18","conditions":"Meningitis, Bacterial, Neisseria Infection","enrollment":35},{"nctId":"NCT02505581","phase":"PHASE4","title":"Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-05","conditions":"Surgical Wound Infection","enrollment":536},{"nctId":"NCT03431675","phase":"PHASE4","title":"Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018","status":"WITHDRAWN","sponsor":"Epicentre","startDate":"2019-03-01","conditions":"Meningitis, Meningococcal","enrollment":""},{"nctId":"NCT01505634","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-16","conditions":"Urinary Tract Infections, Pyelonephritis","enrollment":302},{"nctId":"NCT02734732","phase":"PHASE2","title":"Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2015-04","conditions":"Prostate Infection","enrollment":2800},{"nctId":"NCT01952444","phase":"PHASE1","title":"Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers","status":"COMPLETED","sponsor":"Elusys Therapeutics","startDate":"2013-10-29","conditions":"Inhalational Anthrax","enrollment":40},{"nctId":"NCT03150082","phase":"PHASE1","title":"Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-01","conditions":"Infections, Bacterial","enrollment":26},{"nctId":"NCT03084601","phase":"PHASE4","title":"Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy","status":"COMPLETED","sponsor":"Mahmoud M Saadoon","startDate":"2017-03-01","conditions":"Necrotic Pulp, Postoperative Pain","enrollment":100},{"nctId":"NCT01733966","phase":"PHASE3","title":"A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults","status":"TERMINATED","sponsor":"Quanta Medical","startDate":"2010-05","conditions":"Diverticular Sigmoïditis","enrollment":100},{"nctId":"NCT03347461","phase":"PHASE4","title":"Otiprio Versus Ciprodex Tympanostomy Tube Outcomes","status":"WITHDRAWN","sponsor":"Boston Medical Center","startDate":"2018-10","conditions":"Otorrhea, Otitis Media With Effusion in Children","enrollment":""},{"nctId":"NCT02724046","phase":"PHASE4","title":"Ciprofloxacin for the Prevention of Meningococcal Meningitis","status":"COMPLETED","sponsor":"Epicentre","startDate":"2017-04-22","conditions":"Meningitis, Meningococcal","enrollment":300},{"nctId":"NCT02304822","phase":"NA","title":"Comparison of Multiple-, Single- and Zero-dose of Ciprofloxacin Prophylaxis in Retrograde Intrarenal Surgery","status":"UNKNOWN","sponsor":"Guohua Zeng","startDate":"2014-08","conditions":"Kidney Stones","enrollment":450},{"nctId":"NCT01014013","phase":"PHASE3","title":"Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Urinary Tract Infection","enrollment":271},{"nctId":"NCT02118909","phase":"PHASE1","title":"Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2014-05","conditions":"Healthy Volunteers, Non-smokers","enrollment":32},{"nctId":"NCT00214331","phase":"","title":"Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-04","conditions":"Pregnancy","enrollment":150},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT00670215","phase":"PHASE3","title":"BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-04","conditions":"Bacterial Infections","enrollment":497},{"nctId":"NCT01538667","phase":"PHASE1","title":"Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-04","conditions":"Respiratory System","enrollment":24},{"nctId":"NCT01110421","phase":"PHASE3","title":"A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection","enrollment":7},{"nctId":"NCT01110408","phase":"PHASE3","title":"A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Complicated Urinary Tract Infections or Pyelonephritis","enrollment":41},{"nctId":"NCT01168895","phase":"PHASE1","title":"Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":"Infection, Pulmonary Disease, Chronic Obstructive","enrollment":12},{"nctId":"NCT00961038","phase":"PHASE1","title":"Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT02015507","phase":"PHASE1","title":"An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-01","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT00097773","phase":"PHASE2","title":"Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-09","conditions":"Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive","enrollment":304},{"nctId":"NCT01768663","phase":"PHASE1","title":"A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Cystic Fibrosis","enrollment":80},{"nctId":"NCT01052298","phase":"PHASE1","title":"Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04","conditions":"Disease, Pulmonary","enrollment":25},{"nctId":"NCT00062231","phase":"NA","title":"Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-04","conditions":"Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes, Infection","enrollment":351},{"nctId":"NCT00785980","phase":"PHASE1","title":"Drug - Drug Interaction Study of Quinine Sulfate and Ciprofloxacin","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2008-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00741052","phase":"PHASE3","title":"Ciprofloxacin Multiple Dose for Adult Cholera","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2007-07","conditions":"Cholera","enrollment":218},{"nctId":"NCT01372345","phase":"PHASE1","title":"Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2005-02","conditions":"Fasting","enrollment":43},{"nctId":"NCT01372358","phase":"PHASE1","title":"Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2005-01","conditions":"Fed","enrollment":32},{"nctId":"NCT00138411","phase":"PHASE1","title":"Monoclonal Antibody for Treatment of Inhalation Anthrax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Bacillus Anthracis (Anthrax)","enrollment":36},{"nctId":"NCT00598403","phase":"PHASE3","title":"Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis","status":"COMPLETED","sponsor":"Tedec-Meiji Farma, S.A.","startDate":"2007-11","conditions":"Urinary Tract Infections","enrollment":611},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75},{"nctId":"NCT00229944","phase":"PHASE3","title":"Single Dose Azithromycin in the Treatment of Adult Cholera","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2002-12","conditions":"Cholera","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":487,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ciprofloxacin single dose","genericName":"Ciprofloxacin single dose","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Acute bacterial infections (respiratory, urinary tract, gastrointestinal, skin), Gonorrhea (single-dose regimen), Traveler's diarrhea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}